Skip to main content
TrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor about whether a trial is right for you.

Alexion Pharmaceuticals, Inc.

5 clinical trials · 5 recruiting · INDUSTRY

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

Trials by Alexion Pharmaceuticals, Inc.

RECRUITINGNCT06312644

Study of Ultomiris® (Ravulizumab) Safety in Pregnancy

The primary objective of this study is to describe the frequency and characteristics of pregnancy outcomes and maternal complications among participants exposed to Ultomiris and...

Sponsor: Alexion Pharmaceuticals, Inc.Enrolling: 758 locations
Ultomiris-exposed Pregnant/ PostpartumPregnancyParoxysmal Nocturnal Hemoglobinuria (PNH)+3
RECRUITINGNCT04202341

Registry of Participants With Generalized Myasthenia Gravis Treated With Alexion C5 Inhibition Therapies (C5ITs)

Long-term, multicenter, multinational, observational, registry of patients with gMG that is designed to collect data on clinical outcomes and safety in patients prescribed Alexion...

Sponsor: Alexion Pharmaceuticals, Inc.Enrolling: 50020 locations
Generalized Myasthenia Gravis
RECRUITINGPhase 3NCT06607627

PK, PD, Safety, and Efficacy Study of Gefurulimab in Pediatric Patients With AChR+ Generalized Myasthenia Gravis

The primary objective of this study is to assess the pharmacokinetics and pharmacodynamics of gefurulimab in pediatric participants with AChR+ gMG for the duration of the study.

Sponsor: Alexion Pharmaceuticals, Inc.Enrolling: 1213 locations
Generalized Myasthenia GravisgMG
RECRUITINGNCT06967480

Early Ravulizumab Treatment Of Anti- AChR Antibody-Positive Generalized Myasthenia Gravis

The primary objective of the study is to evaluate the effectiveness of Ravulizumab in improving MG-ADL in an early-stage AChR+ gMG population.

Sponsor: Alexion Pharmaceuticals, Inc.Enrolling: 4020 locations
Generalized Myasthenia GravisAnti-AChR Antibody Positive
RECRUITINGPhase 2NCT07160608

Safety and Efficacy of Tarperprumig in Adult Participants With Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated...

The primary objective of this study is to evaluate the safety and tolerability of tarperprumig in participants with newly diagnosed or relapsing anti-neutrophil cytoplasmic...

Sponsor: Alexion Pharmaceuticals, Inc.Enrolling: 7520 locations
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis